Intra-Cellular Therapies (ITCI) Tops Q4 EPS by 9c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update
February 25, 2021 7:30 AM ESTSuccessfully launched CAPLYTA® (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19.
CAPLYTA achieved net product revenues of $12.4 million and $22.5 million for fourth quarter and full year 2020, respectively.
Fourth quarter CAPLYTA total prescriptions (TRx) increased 77% versus the previous quarter.
Pursuing CAPLYTA label expansion including bipolar depression and major depressive disorder:
Submitted CAPLYTA supplemental new drug applications (sNDAs) to the FDA... More